SEARCH

SEARCH BY CITATION

References

  • Altekruse, S.F., Kosary, C.L., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Ruhl, J., Howlader, N., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M.P., Lewis, D.R., Cronin, K., Chen, H.S., Feuer, E.J., Stinchcomb, D.G. & Edwards, B.K. (eds) (2010) SEER Cancer Statistics Review: 1975–2007. National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site.
  • Anderson, K.C. (2003) Multiple myeloma: how far have we come? Mayo Clinic Proceedings, 78, 1517.
  • Arnulf, B., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., van de Velde, H., Feng, H., Cakana, A., Deraedt, W. & Moreau, P. (2012) Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica, [Epub ahead of print]. doi:10.3324/haematol.2012.067793.
  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. The New England Journal of Medicine, 335, 9197.
  • Berdeja, J.G., Couriel, D.R., Murphy, P., Boccia, R.V., Priego, V., Hainsworth, J.D., Macias-Pérez, I.M. & Flinn, I.W. (2011) A phase II trial of combined bendamustine, bortezomib and dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not candidates for high-dose chemotherapy: results of a planned interim safety analysis. Blood, 118, Abstract 2943.
  • Berenson, J.R., Yang, H.H., Sadler, K., Jarutirasarn, S.G., Vescio, R.A., Mapes, R., Purner, M., Lee, S.P., Wilson, J., Morrison, B., Adams, J., Schenkein, D. & Swift, R. (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 24, 937944.
  • Berenson, J.R., Yellin, O., Woytowitz, D., Flam, M.S., Cartmell, A., Patel, R., Duvivier, H., Nassir, Y., Eades, B., Abaya, C.D., Hilger, J. & Swift, R.A. (2009) Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. European Journal of Haematology, 82, 433439.
  • Berenson, J.R., Yellin, O., Chen, C.S., Patel, R., Bessudo, A., Boccia, R.V., Yang, H.H., Vescio, R., Yung, E., Mapes, R., Eades, B., Hilger, J.D., Wirtschafter, E., Hilger, J., Nassir, Y. & Swift, R.A. (2011) A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. British Journal of Haematology, 155, 580587.
  • Berenson, J.R., Yellin, O., Kazamel, T., Hilger, J.D., Chen, C.S., Cartmell, A., Woliver, T., Flam, M., Bravin, E., Nassir, Y., Vescio, R. & Swift, R.A. (2012) A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia, 26, 16751680.
  • Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 11151123.
  • Bladé, J., Rosinol, L., Sureda, A., Ribera, J.M., Díaz-Mediavilla, J., García-Laraña, J., Mateos, M.V., Palomera, L., Fernández-Calvo, J., Martí, J.M., Giraldo, P., Carbonell, F., Callís, M., Trujillo, J., Gardella, S., Moro, M.J., Barez, A., Soler, A., Font, L., Fontanillas, M. & San Miguel, J. (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood, 106, 37553759.
  • Brinker, B.T., Waller, E.K., Leong, T., Heffner, Jr, L.T., Redei, I., Langston, A.A. & Lonial, S. (2006) Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer, 106, 21712180.
  • Cavo, M., Rajkumar, S.V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., Sezer, O., Ludwig, H., Dimopoulos, M.A., Attal, M., Sonneveld, P., Boccadoro, M., Anderson, K.C., Richardson, P.G., Bensinger, W., Johnsen, H.E., Kroeger, N., Gahrton, G., Bergsagel, P.L., Vesole, D.H., Einsele, H., Jagannath, S., Niesvizky, R., Durie, B.G., San Miguel, J. & Lonial, S. (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 117, 60636073.
  • Cheson, B.D. & Rummel, M.J. (2009) Bendamustine: rebirth of an old drug. Journal of Clinical Oncology, 27, 14921501.
  • Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine, 348, 18751883.
  • Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England Journal of Medicine, 357, 21232132.
  • Durie, B.G., Harousseau, J.L., Miguel, J.S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G., Rajkumar, S.V. & International Myeloma Working Group. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 14671473. Erratum in: Leukemia (2006), 20, 2220; Leukemia (2007) 21, 1134.
  • Fenk, R., Michael, M., Zohren, F., Graef, T., Czibere, A., Bruns, I., Neumann, F., Fenk, B., Haas, R. & Kobbe, G. (2007) Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 48, 23452351.
  • Gay, F., Hayman, S.R., Lacy, M.Q., Buadi, F., Gertz, M.A., Kumar, S., Dispenzieri, A., Mikhael, J.R., Bergsagel, P.L., Dingli, D., Reeder, C.B., Lust, J.A., Russell, S.J., Roy, V., Zeldenrust, S.R., Witzig, T.E., Fonseca, R., Kyle, R.A., Greipp, P.R., Stewart, A.K. & Rajkumar, S.V. (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood, 115, 13431350.
  • Gregory, W.M., Richards, M.A. & Malpas, J.S. (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology, 10, 334342.
  • Grey-Davies, E., Bosworth, J.L., Boyd, K.D., Ebdon, C., Saso, R., Chitnavis, D., Mercieca, J.E., Morgan, G.J. & Davies, F.E. (2011) Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. British Journal of Haematology, 156, 552555; author reply 555.
  • Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P.G., Niesvizky, R., Alexanian, R., Limentani, S.A., Alsina, M., Adams, J., Kauffman, M., Esseltine, D.L., Schenkein, D.P. & Anderson, K.C. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology, 127, 165172.
  • Kumar, S. (2010) Treatment of newly diagnosed multiple myeloma: advances in current therapy. Medical Oncology (Northwood, London, England), 27, S14S24.
  • Kumar, S., Flinn, I., Richardson, P.G., Hari, P., Callander, N., Noga, S.J., Stewart, A.K., Turturro, F., Rifkin, R., Wolf, J., Estevam, J., Mulligan, G., Shi, H., Webb, I.J. & Rajkumar, S.V. (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 119, 43754382.
  • Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.E., Therneau, T.M. & Greipp, P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 2133.
  • Lentzsch, S., O'Sullivan, A., Kennedy, R.C., Abbas, M., Dai, L., Pregja, S.L., Burt, S., Boyiadzis, M., Roodman, G.D., Mapara, M.Y., Agha, M., Waas, J., Shuai, Y., Normolle, D. & Zonder, J.A. (2012) Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood, 119, 46084613.
  • Leoni, L.M., Bailey, B., Reifert, J., Bendall, H.H., Zeller, R.W., Corbeil, J., Elliott, G. & Niemeyer, C.C. (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clinical Cancer Research, 14, 309317.
  • Ludwig, H., Kasparu, H., Linkesch, W., Thaler, J., Greil, R., Leitgeb, C., Heintel, D., Rauch, E., Zojer, N., Pour, L., Seebacher, A. & Adam, Z. (2011) Bortezomib-bendamustine-dexamethasone in patients with relapsed/refractory multiple myeloma (MM) shows marked efficacy and is well tolerated, but assessment of PNP symptoms shows significant discrepancies between patients and physicians. Blood (ASH Annual Meeting Abstracts), 118, 2928.
  • Ma, M.H., Yang, H.H., Parker, K., Manyak, S., Friedman, J.M., Altamirano, C., Wu, Z.Q., Borad, M.J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R.A. & Berenson, J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 9, 11361144.
  • Mateos, M.V., Richardson, P.G., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & San Miguel, J.F. (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. Journal of Clinical Oncology, 28, 22592266.
  • Orlowski, R.Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, H.J., Suvorov, A.N., Zhuang, S.H., Parekh, T., Xiu, L., Yuan, Z., Rackoff, W. & Harousseau, J.L. (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of Clinical Oncology, 25, 38923901.
  • Owen, J.S., Melhem, M., Passarell, J.A., D'Andrea, D., Darwish, M. & Kahl, B. (2010) Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemotherapy and Pharmacology, 66, 10391049.
  • Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., Benevolo, G., Callea, V., Baldini, L., Morabito, F., Grasso, M., Leonardi, G., Rizzo, M., Falcone, A.P., Gottardi, D., Montefusco, V., Musto, P., Petrucci, M.T., Ciccone, G. & Boccadoro, M. (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of Clinical Oncology, 28, 51015109.
  • Piro, E. & Molica, S. (2011) A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence? Acta Haematologica, 126, 163168.
  • Pönisch, W. & Niederwieser, D. (2002) Bendamustine in the treatment of multiple myeloma: results and future perspectives. Seminars in Oncology, 29, 2326.
  • Pönisch, W., Mitrou, P.S., Merkle, K., Herold, M., Assmann, M., Wilhelm, G., Dachselt, K., Richter, P., Schirmer, V., Schulze, A., Subert, R., Harksel, B., Grobe, N., Stelzer, E., Schulze, M., Bittrich, A., Freund, M., Pasold, R., Friedrich, T., Helbig, W. & Niederwieser, D. (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Journal of Cancer Research and Clinical Oncology, 132, 205212.
  • Pönisch, W., Bourgeois, M., Wang, S.Y., Heyn, S., Jäkel, N., Braunert, L., Pfannes, R., Nehring, C., Nehring, C., Becker, C., Becker, C., Al Ali, H., Hensel, G. & Niederwieser, D. (2007) A combination chemotherapy with bortezomib, bendamustine and prednisone for patients with refractory/relapsed multiple myeloma: a unicentric retrospective trial. Haematologica, 92, Abstract 1178.
  • Pönisch, W., Rozanski, M., Goldschmidt, H., Hoffmann, F.A., Boldt, T., Schwarzer, A., Ritter, U., Rohrberg, R., Schwalbe, E., Uhlig, J., Zehrfeld, T., Schirmer, V., Haas, A., Kreibich, U., Niederwieser, D. & East German Study Group of Haematology ad Oncology (OSHO). (2008) Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. British Journal of Haematology, 143, 191200.
  • Pönisch, W., Andrea, M., Wagner, I., Hammerschmidt, D., Kreibich, U., Schwarzer, A., Zehrfeld, T., Schwarz, M., Winkelmann, C., Petros, S., Bachmann, A., Lindner, T. & Niederwieser, D. (2012) Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. Journal of Cancer Research and Clinical Oncology, 138, 14051412.
  • Rajkumar, S.V., Gertz, M.A., Kyle, R.A. & Greipp, P.R. (2002) Current therapy for multiple myeloma. Mayo Clinic Proceedings, 77, 813822.
  • Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology, 11, 2937.
  • Ramasamy, K., Hazel, B., Mahmood, S., Corderoy, S. & Schey, S. (2011) Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. British Journal of Haematology, 155, 632634.
  • Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine, 348, 26092617.
  • Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Bladé, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine, 352, 24872498.
  • Richardson, P.G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Miguel, J.S., Bladé, J., Boccadoro, M., Cavenagh, J., Alsina, M., Rajkumar, S.V., Lacy, M., Jakubowiak, A., Dalton, W., Boral, A., Esseltine, D.L., Schenkein, D. & Anderson, K.C. (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood, 110, 35573560.
  • Roussel, M., Moreau, P., Huynh, A., Mary, J.Y., Danho, C., Caillot, D., Hulin, C., Fruchart, C., Marit, G., Pégourié, B., Lenain, P., Araujo, C., Kolb, B., Randriamalala, E., Royer, B., Stoppa, A.M., Dib, M., Dorvaux, V., Garderet, L., Mathiot, C., Avet-Loiseau, H., Harousseau, J.L. & Attal, M. (2010) Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM). Blood, 115, 3237.
  • San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. The New England Journal of Medicine, 359, 906917.
  • Strumberg, D., Harstrick, A., Doll, K., Hoffmann, B. & Seeber, S. (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anti-Cancer Drugs, 7, 415421.
  • Zhang, S., Wang, X., Chen, L., Liang, J., Suvannasankha, A., Abonour, R. & Farag, S.S. (2008) Synergistic activity of bendamustine in combination with doxorubicin and bortezomib in multiple myeloma cells. Blood, 112, Abstract 5171.